The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear.
about
A Novel Prioritization Method in Identifying Recurrent Venous Thromboembolism-Related GenesIdentification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion.Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.Activity of fibroblast growth factor receptor inhibitors TKI258, ponatinib and AZD4547 against TPR‑FGFR1 fusionTyrosine Kinase Inhibitors and Vascular Toxicity: Impetus for a Classification System?Oncocardiology-Past, Present, and Future: A Review.Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia.Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab.Eradication of T315I mutation in chronic myeloid leukemia without third-generation tyrosine kinase inhibitor: a case report.Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy.The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model.Ponatinib Activates an Inflammatory Response in Endothelial Cells via ERK5 SUMOylationMechanism and Management of Cancer Chemotherapy-Induced Atherosclerosis
P2860
Q28551214-442A1505-CBAD-4CED-BCD2-08AF6243322FQ30245010-F78A1269-E4AD-4B6F-870B-C73137D4233AQ36316309-72D9D878-9EE3-462B-844E-73F3B73B9440Q38718712-9D5A0FED-CDCB-42A9-AF2A-07C85665B6A8Q38813467-720C636D-1AAA-4921-A3D2-F938B51C3B37Q38829737-4DA8C5A3-7FD5-4FFC-98C1-E524AF87AFDDQ39186183-877ABA64-5097-470F-B4DD-9E6EF177B26BQ52641875-67707B9B-A84D-420A-BC2B-467A78943815Q54121709-7C08DC3F-3D67-4634-877E-59E31878B7DFQ54273566-06CEA671-5F23-4B07-BCEF-22BDF3250BF2Q55398181-02C18AB0-EAF9-4FCB-84D2-94452F6C5FBBQ55401609-2246C0DE-E1AE-45C9-B093-DE26EB859F11Q58761411-B6CDF6BA-92AB-4B12-BC7B-02156EAAF0CBQ58791422-70741D89-DA8F-495F-925B-30AF0E103CE0
P2860
The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The BCR-ABL inhibitor ponatini ...... gregate formation under shear.
@ast
The BCR-ABL inhibitor ponatini ...... gregate formation under shear.
@en
The BCR-ABL inhibitor ponatini ...... gregate formation under shear.
@nl
type
label
The BCR-ABL inhibitor ponatini ...... gregate formation under shear.
@ast
The BCR-ABL inhibitor ponatini ...... gregate formation under shear.
@en
The BCR-ABL inhibitor ponatini ...... gregate formation under shear.
@nl
prefLabel
The BCR-ABL inhibitor ponatini ...... gregate formation under shear.
@ast
The BCR-ABL inhibitor ponatini ...... gregate formation under shear.
@en
The BCR-ABL inhibitor ponatini ...... gregate formation under shear.
@nl
P2093
P2860
P1433
P1476
The BCR-ABL inhibitor ponatini ...... gregate formation under shear.
@en
P2093
András Gruber
Cassandra P Loren
Laura D Healy
Marie S Nowak
Owen J T McCarty
Rachel A Rigg
P2860
P304
P356
10.1016/J.THROMRES.2014.11.009
P577
2014-11-18T00:00:00Z